Sanofi

Sanofi-aventis

Philippe Delay-Goyet

Thomas Rooney

Pascal Barneoud

Veronique Blanchard-Bregeon

Badia Ferzaz

Corinne Perron

Mathilde Lopez-Grancha

Véronique Blanchard-Bregeon

Jocelyne Lolivier

Jean Menager

Veronique Mary

Nathalie Schussler

Claire Delgorge

Christine Menet

Mathilde Lopez Grancha

Véronique Mary

Christine Ravinet-Trillou

Gilles Poughon

This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.

H3 receptor antagonist for use in the treatment of alzheimer's disease

The invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of cerebral traumas.

[object Object]

The present invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide, in the form of a hydrate, of a solvate, of a base or of an addition salt with an acid, for the preparation of a medicament for use in the treatment of spinal cord traumas.

Growing community of inventors

Paris, France

Philippe Delay-Goyet